Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Clinics (Sao Paulo) ; 76: e3548, 2021.
Article in English | MEDLINE | ID: covidwho-1559615

ABSTRACT

OBJECTIVES: In this preliminary study we investigated cellular and humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens in blood samples from 14 recovered coronavirus disease 2019 (COVID-19) patients and compared them to those in samples from 12 uninfected/unvaccinated volunteers. METHODS: Cellular immunity was assessed by intracellular detection of IFN-γ in CD3+ T lymphocytes after stimulation with SARS-CoV-2 spike (S1), nucleocapsid (NC), or receptor-binding domain (RBD) recombinant proteins or overlapping peptide pools covering the sequence of SARS-CoV-2 spike, membrane and nucleocapsid regions. The humoral response was examined by ELISAs and/or chemiluminescence assays for the presence of serum IgG antibodies directed to SARS-CoV-2 proteins. RESULTS: We observed differences between humoral and cellular immune profiles in response to stimulation with the same proteins. Assays of IgG antibodies directed to SARS-CoV-2 NC, RBD and S1/S2 recombinant proteins were able to differentiate convalescent from uninfected/unvaccinated groups. Cellular immune responses to SARS-CoV-2 protein stimuli did not exhibit a specific response, as T cells from both individuals with no history of contact with SARS-CoV-2 and from recovered donors were able to produce IFN-γ. CONCLUSIONS: Determination of the cellular immune response to stimulation with a pool of SARS-CoV-2 peptides but not with SARS-CoV-2 proteins is able to distinguish convalescent individuals from unexposed individuals. Regarding the humoral immune response, the screening for serum IgG antibodies directed to SARS-CoV-2 proteins has been shown to be specific for the response of recovered individuals.


Subject(s)
COVID-19 , SARS-CoV-2 , Antibodies, Viral , Humans , Immunity, Humoral , Recombinant Proteins , Spike Glycoprotein, Coronavirus
2.
Rev Inst Med Trop Sao Paulo ; 62: e91, 2020.
Article in English | MEDLINE | ID: covidwho-1073182

ABSTRACT

Coronavirus disease 19 (COVID-19) is caused by SARS-Cov-2 and the manifestations of this infection range from an absence of symptoms all the way up to severe disease leading to death. To estimate the prevalence of past infection in a population, the most readily available method is the detection of antibodies against the virus. This study has investigated the prevalence of anti-SARS-CoV-2 antibodies in outpatients of the Hospital das Clinicas, in Sao Paulo city (Brazil), which is a large university hospital belonging to the public health system that cares for patients with complex diseases who need tertiary or quaternary medical care. Our serological inquiry was carried out for 6 weeks, with once-a-week blood sampling and included 439 patients from several outpatient services. Overall, 61 patients tested positive for anti-SARS-CoV-2 IgG (13.9%); 56.1 % of the patients live in Sao Paulo city, with the remaining living in other towns of the metropolitan area; 32.8% of the patients testing positive for IgG antibodies to SARS-CoV-2 were asymptomatic, 55.7% developed mild or moderate disease and 11.5% had to be hospitalized. The prevalence of SARS-CoV-2 positive serology was lower among patients who had received the seasonal influenza vaccine compared to the ones who did not. These findings may indicate that those individuals care more about health issues, and/or that they have a better access to health care and/or a better quality of health care service. The large proportion of patients who were unaware of having had contact with SARS-CoV-2 deserves attention, reflecting the scarcity of tests performed in the population.


Subject(s)
Antibodies, Viral/blood , Coronavirus Infections/diagnosis , Outpatients , Pneumonia, Viral/diagnosis , Betacoronavirus , Brazil/epidemiology , COVID-19 , Humans , Pandemics , Prevalence , SARS-CoV-2 , Seroepidemiologic Studies
3.
Front Immunol ; 11: 1672, 2020.
Article in English | MEDLINE | ID: covidwho-685034

ABSTRACT

Pregnancy comprises a unique immunological condition, to allow fetal development and to protect the host from pathogenic infections. Viral infections during pregnancy can disrupt immunological tolerance and may generate deleterious effects on the fetus. Despite these possible links between pregnancy and infection-induced morbidity, it is unclear how pregnancy interferes with maternal response to some viral pathogens. In this context, the novel coronavirus (SARS-CoV-2) can induce the coronavirus diseases-2019 (COVID-19) in pregnant women. The potential risk of vertical transmission is unclear, babies born from COVID-19-positive mothers seems to have no serious clinical symptoms, the possible mechanisms are discussed, which highlights that checking the children's outcome and more research is warranted. In this review, we investigate the reports concerning viral infections and COVID-19 during pregnancy, to establish a correlation and possible implications of COVID-19 during pregnancy and neonatal's health.


Subject(s)
Betacoronavirus , Coronavirus Infections/immunology , Coronavirus Infections/transmission , Pneumonia, Viral/immunology , Pneumonia, Viral/transmission , Pregnancy Complications, Infectious/immunology , Pregnancy Complications, Infectious/virology , COVID-19 , Child, Preschool , Coronavirus Infections/blood , Coronavirus Infections/virology , Cytokines/blood , Female , Fetal Development/immunology , Humans , Infant , Infant, Newborn , Infectious Disease Transmission, Vertical , Mothers , Pandemics , Pneumonia, Viral/blood , Pneumonia, Viral/virology , Pregnancy , Pregnancy Complications, Infectious/blood , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL